Archive for March 2019

We tested the hypothesis that brain arterial dilatation increases the risk of Alzheimer’s dementia (AD).

Examining 106 subjects aged 60-97 years, Sasaki [1] recently found parkinsonism (rigidity, resting tremor, reduced dopamine transporter in basal ganglia) in 52.8% of cases with mild cognitive impairment (MCI; n = 63) or mild Alzheimer’s disease (AD; n = 43). Their mean age (80.6 ± 6.1 SD years) was significantly higher than those without extrapyramidal signs (EPS) (77.6 ± 7.0 SD years). In contrast…

Four less well-studied but promising “emerging” cerebrospinal fluid (CSF) biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin, synaptosomal-associated protein-25 (SNAP-25), visinin-like protein 1 (VILIP-1), and chitinase-3-like protein 1 (YKL-40).

Recent research with neuropathologic or biomarker evidence of Alzheimer’s disease (AD) casts doubt on traumatic brain injury (TBI) as a risk factor for AD. We leveraged the National Alzheimer’s Coordinating Center to examine the association between self-reported TBI with loss of consciousness and AD neuropathologic changes, and with baseline and longitudinal clinical status.

Recruitment for Alzheimer’s disease (AD) prevention research studies is challenging because of lack of awareness among cognitively healthy adults coupled with the high screen fail rate due to participants not having a genetic risk factor or biomarker evidence of the disease. Participant recruitment registries offer one solution for efficiently and effectively identifying, characterizing, and connecting…

Primary progressive aphasia (PPA) displays variable progression trajectories that require further elucidation.

The tau protein plays a central role in Alzheimer’s disease (AD), and there is huge interest in measuring tau in blood and cerebrospinal fluid (CSF).

Murine microglia expressing the Alzheimer’s disease–linked TREM2R47H mutation display variable decrease in phagocytosis, while impaired phagocytosis is reported following loss of TREM2. However, no data exist on TREM2+/R47H human microglia. Therefore, we created human pluripotent stem cell (hPSC) monocytes and transdifferentiated microglia-like cells (tMGs) to examine the effect of the TREM2+/R47H mutation and loss of…

We explored regional brain atrophy patterns and their clinical correlates in dementia with Lewy bodies (DLB).

This study tested if central obesity, hypertension, or depressive symptoms moderated the relationship between β-amyloid (Aβ) and longitudinal cognitive performance in late middle-aged adults enriched for Alzheimer’s disease (AD) risk.